Literature DB >> 23566289

Serum Soluble-Fas, Inflammation, and Anemia in Acute Kidney Injury.

Miguel Angelo Góes1, Ilson Jorge Iizuka1,2, Beata Marie Quinto1, Maria Aparecida Dalboni1, Julio César Monte1,2, Bento Cardoso Santos1,2, Oscar Fernando Pavão Dos Santos1,2, Virgilio Gonçalves Pereira2, Marcelino de Souza Durão1,2, Marcelo Costa Batista1,2, Miguel Cendoroglo1,2,3.   

Abstract

Anemia is a common feature in critically ill patients. Serum soluble-Fas (sFas) levels are associated with anemia in chronic kidney disease. It is possible that sFas levels are also associated with anemia in acute kidney injury (AKI) patients. The study aims to investigate the relationship between serum levels of sFas, erythropoietin (Epo), inflammatory cytokines, and hemoglobin (Hb) concentration in critically ill patients with AKI. We studied 72 critically ill patients with AKI (AKI group; n = 53) or without AKI (non-AKI group; n = 19), and 18 healthy volunteers. Serum sFas, Epo, tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6, IL-10, iron status, and Hb concentration were analyzed in all groups. We also investigated the correlation between these variables in the AKI group. Critically ill patients (AKI and non-AKI groups) had higher serum levels of Epo than healthy volunteers. Hb concentration was lower in the AKI group than in the other groups. Serum sFas, IL-6, TNF-α, and ferritin levels were higher in the AKI group. Hb concentration correlated negatively with serum IL-6 (r = -0.37, P = 0.008), sFas (r = -0.35, P = 0.01), and Epo (r = -0.27, P = 0.04), while serum sFas correlated positively with iron levels (r = 0.36, P = 0.008) and IL-6 (r = 0.28, P = 0.04) in the AKI group. In multivariate analysis, after adjusting for markers of inflammation and iron stores, only serum sFas levels (P = 0.03) correlated negatively with Hb concentration in the AKI group. Serum Epo and inflammatory cytokine levels are elevated in critically ill patients with or without AKI. Serum levels of sFas are elevated and independently associated with anemia in critically ill patients with AKI.
© 2013, Copyright the Authors. Artificial Organs © 2013, International Center for Artificial Organs and Transplantation and Wiley Periodicals, Inc.

Entities:  

Keywords:  Acute kidney injury; Anemia; Erythropoietin; Inflammation; Soluble sFas

Mesh:

Substances:

Year:  2013        PMID: 23566289     DOI: 10.1111/aor.12019

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  4 in total

1.  Soluble Fas affects erythropoiesis in vitro and acts as a potential predictor of erythropoiesis-stimulating agent therapy in patients with chronic kidney disease.

Authors:  Daniela Mendes Chiloff; Danilo Candido de Almeida; Maria A Dalboni; Maria Eugênia Canziani; Sunil K George; Alshaimaa Mahmoud Morsi; Nadia El-Akabawy; Christopher D Porada; Marcelino Souza Durao; Abolfazl Zarjou; Graca Almeida-Porada; Miguel Angelo Goes
Journal:  Am J Physiol Renal Physiol       Date:  2020-01-31

2.  Serum soluble-Fas is a predictor of red blood cell transfusion in critically ill patients.

Authors:  Ilana Levy Korkes; Gustavo Schvartsman; Ilson Jorge Lizuka; Beata Marie Quinto; Maria Aparecida Dalboni; Maria Eugênia Canziani; Sergio Antonio Draibe; Virgilio Gonçalves Pereira; Bento Fortunato Cardoso Dos Santos; Julio Cesar Martins Monte; Marcelino de Souza Durão Junior; Marcelo Costa Batista; Oscar Fernando Pavão Dos Santos; Miguel Angelo de Góes Junior; Miguel Cendoroglo Neto
Journal:  Einstein (Sao Paulo)       Date:  2013-12

3.  Circulating levels of soluble Fas (sCD95) are associated with risk for development of a nonresolving acute kidney injury subphenotype.

Authors:  Pavan K Bhatraju; Cassianne Robinson-Cohen; Carmen Mikacenic; Susanna Harju-Baker; Victoria Dmyterko; Natalie S J Slivinski; W Conrad Liles; Jonathan Himmelfarb; Susan R Heckbert; Mark M Wurfel
Journal:  Crit Care       Date:  2017-08-17       Impact factor: 9.097

4.  Acute kidney injury: Incidence, risk factors, and outcomes in severe COVID-19 patients.

Authors:  Danilo Candido de Almeida; Maria do Carmo Pinho Franco; Davi Rettori Pardo Dos Santos; Marina Colella Santos; Isabela Soucin Maltoni; Felipe Mascotte; Alexandra Aparecida de Souza; Paula Massaroni Pietrobom; Eduardo Alexandrino Medeiros; Paulo Roberto Abrão Ferreira; Flavia Ribeiro Machado; Miguel Angelo Goes
Journal:  PLoS One       Date:  2021-05-25       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.